The quantity of therapeutic gene products released from genetically engineered cells can be controlled externally at different levels. The widely used approach of controlling expression, however, generally has the disadvantage that chemical substances must be applied for stimulation. An alternative strategy aims at controlling gene products at posttranslational levels such as secretion. The secretion of a therapeutic agent can be regulated if the agent is targeted to the regulated secretory pathway and stored in the secretory granules until its release. In this article we address the question of whether the release of β-endorphin, an opioid with a potent analgesic effect, could be induced by electrically stimulating stably transfected Neuro-2a cells. Throughout this study we used the human proopiomelanocortin (POMC) gene, which is the precursor molecule for human β-endorphin. We analyzed its subcellular localization and found it in the regulated secretory pathway in Neuro-2a cells. Using electrical field stimulation we were able to identify a stimulation pattern that significantly increased the release of β-endorphin-immunoreactive material, although to a limited extent. This result indicates that electrical stimulation of secretion could be used to manipulate the amount of a therapeutic agent released from transplanted cells.
INTRODUCTION
tion systems, have been used to control β-endorphin on the transcriptional level (5, 13, 17) . Furthermore, a study conducted by Sagen et al. in 1993 reports the control of The transplantation of cells expressing opioid peptides is an attractive alternative for the treatment of se-the secretion of antinociceptive substances by the application of nicotine (12). All the above systems proved vere chronic pain, which is otherwise only poorly manageable (11). β-Endorphin is a 31-amino acid opioid practicable, but they require the application of a chemical agent as a stimulus. Such chemical agents exert their peptide with excellent analgesic properties. On the molar level, β-endorphin is 21 times as potent as morphine effects in the whole human body, causing unwanted side effects. Insomnia and indigestion/epigastric discomfort when given intrathecally (18) . β-Endorphin application leads to an elevation of the nociceptive threshold in the have been, among other side effects, associated with dexamethasone treatment (16) ; use of antibiotics like discrete trial shock titration task (18) as well as in a neuropathic pain model (8). Furthermore, β-endorphin doxycyline promote antibiotic resistance (3) and nicotine is known to exert toxic effects on the pancreas and causes analgesic effects in hot-plate, tail pinch, and formalin tests (5, 14) .
is a psychoactive substance causing dependence (9).
Here we examine the potential use of electrical stim-It would be advantageous to be able to exogenously control the amount of antinociceptive substances re-ulation of genetically engineered cells as a tool for controlling the release of the analgesic substance β-endorleased from transplanted cells. A variety of different induction systems have been tested to date. Two of these, phin. Most induction systems exert their effect at the transcription level. Controlling secretion by electrical the dexamethasone-and doxycycline-mediated induc-544 STORN ET AL. stimulation, however, allows bypassing the time-consum-EGFP fusion sequence were cloned into the EcoRI site of pIRESneo3; the EGFP sequence was cloned into the ing intracellular steps of transcription, posttranscriptional processing, translation, and posttranslational process-EcoRI and NotI sites of pIRESneo3. ing. Neuro-2a cells, which process proopiomelanocortin Immunocytochemistry and Colocalization Analyses (POMC) to β-endorphin (10), were analyzed for their ability to transport human POMC to the regulated secre-Transfected Neuro-2a cells were plated onto glass coverslips coated with poly-D-lysine (BD Biosciences) tory pathway. Next, we applied different electrical stimulation patterns to Neuro-2a cells overexpressing human at a density of 50-80 cells/mm 2 , cultured for 1 h to 3 days, and subsequently fixed in 4% paraformaldeyde POMC and analyzed the effect of the electrical stimulation on the release of β-endorphin.
(Merck, Darmstadt, Germany) in phosphate-buffered saline (PBS) for 10 min. After washing, the specimens MATERIALS AND METHODS were either blocked in 1% bovine serum albumin (PAA) Cell Culture and incubated with primary antibody (anti-carboxypeptidase H, ab11044, Acris Antibodies, Hiddenhausen, Ger-Cells were obtained from T. Danker (Cytocentrics, many) at a dilution of 1:200 in PBS, followed by incuba-Reutlingen, Germany). Neuro-2a cells were cultured in tion with secondary antibody (Cy-3-conjugated goat DMEM high glucose (Cambrex, Verviers, Belgium) anti-rabbit IgG, Jackson Immuno Research Laboratories, with 200 mM glutamine (PAA, Cölbe, Germany) and
Inc., West Grove, USA) at a dilution of 1:100 in PBS, 5% fetal calf serum (PAA). The cells were kept at 37°C, or they were directly mounted in Mowiol (Calbiochem, 5% CO 2 . Neuro-2a cells were transfected using Lipofec-Darmstadt, Germany)/DABCO (Sigma, Deisenhofen, tamine TM 2000 (Invitrogen, Karlsruhe, Germany) with a Germany). Cells were analyzed by confocal microscopy DNA (in µg) to Lipofectamine TM 2000 (in µl) a ratio of using LSM410 Invert and LSM510 Meta microscopes 1:2.4. The selection of stable cell lines was carried out (Zeiss, Oberkochen, Germany). in 800 µg/ml G418.
Electrical Stimulation and RIA Analysis Generation of POMC-EGFP Fusion Molecule
Neuro-2a cells (1.7 and 2.0 × 10 5 ) stably overexpress-The POMC-enhanced green fluorescent protein ing human POMC were seeded into each well of a 24-(POMC-EGFP) fusion molecule was generated by overwell plate. Three days later the cell culture medium was lap extension polymerase chain reaction (PCR). First, removed and the cells were washed once, covered with the human pre-POMC coding region and EGFP coding new culture medium, and stimulated with a variety of region were separately amplified. In these PCRs, overstimulation protocols (see Results) for 1 h or left unstimlaps with the other sequence were generated by the use ulated as controls. A platinum wire (0.4-mm diameter; of specifically designed primers. The sequences of the Goodfellow GmbH, Bad Nauheim, Germany) was used primers were 5′-TGGATCCACCATGCCGAGATCGT as stimulation and bulk electrode. For the electrical GCTG-3′ (CN3F) and5′-TCGCCCTTGCTCACCATCT stimulation of the cells these electrodes were connected CGCCCTTCTTGTAGGC-3′ (CN7R) for the amplificato a stimulator (Stimulus Isolator A395, World Precision tion of the POMC sequence and5′-GCGAGATGGTG Instruments, Berlin, Germany) driven by a pulse genera-AGCAAGGGCGAGGAGCTGTT-3′ (CN7F) and 5′-TGC tor (STG 1008, Multi Channel Systems MCS GmbH, GGCCGCTTACTTGTACAGCTCGTCCATG-3′ (CN8R) Reutlingen, Germany) (see Results). Protocols for the for the amplification of the EGFP sequence. Second, stimulation patterns were designed using the MC_ these amplification products were used as templates in Stimulus II software (Multi Channel Systems MCS the next round of PCR, in which the fusion sequence GmbH). The generated pulses were visualized with an was generated. The primers used for this step were oscilloscope (Oscilloscope 54610B, Hewlett Packard, CN3F and CN8R. The fusion sequence was cloned into Palo Alto, USA). While the same number of pulses pCR2.1-TOPO (Invitrogen) after the addition of sin-(n = 100) was always delivered per burst, the frequency gle 3′ adenine overhangs.
within the bursts (10, 25, and 100 Hz), the intervals be-
Generation of Expression Constructs
tween bursts (10, 16, and 19 s), and the duration of the biphasic rectangular pulses (4 and 10 ms) were varied. The plasmid pIRESneo3 (BD Biosciences Clontech, Heidelberg, Germany) was used to generate all eukaryo-Stimulation device and stimulation patterns were similar to those published by Balkowiec and Katz [(2) and refer-tic expression constructs. pIRESneo3 contains an internal ribosome entry site (IRES) and thus permits the ences therein]. The bursts were given in such a way that the overall number of pulses was kept the same across translation of the gene of interest and the neomycin resistance gene from one single messenger RNA. The hu-the four stimulation protocols. Supernatants were collected and kept at −70°C for analysis. For every single man pre-POMC cDNA sequence and the pre-POMC-stimulation experiment the corresponding unstimulated Neuro-2a cell line, termed NPO037-01, was selected that expressed high levels of human POMC mRNA control was carried out. The only difference between stimulated cultures and their respective controls was that based on quantitative RT-PCR analysis (data not shown).
A specially built stimulation device allowed to expose the stimulation electrodes were not connected to the stimulator for the unstimulated cultures.β-Endorphin ra-cells to electrical field stimulation and simultaneously control the applied stimulation pattern ( Fig. 2A ) (see dioimmunoassay (RIA) was carried out by Rent-a-Lab (Reutlingen, Germany) using a commercially available also Materials and Methods). A total of four different stimulation patterns were tested. The bursts were applied kit for human β-endorphin (Phoenix Pharmaceuticals, Inc., Karlsruhe, Germany). Each sample was analyzed once every 20 s for 60 min with the following stimulation patterns ( Fig. 2B ): (I) bursts of 100 pulses at 10 Hz, in duplicate. Statistical analysis was performed using the Wilcoxon test. A value of p < 0.01 was considered sta-(II) bursts of 100 pulses at 25 Hz, and (III) bursts of 100 pulses at 100 Hz. The duration of the biphasic rectangu-tistically significant. lar pulses in stimulation patterns I-III was always 4 ms.
RESULTS
Stimulation pattern (IV) consisted of 100 pulses at 25 Subcellular Localization of Human POMC Hz, with biphasic rectangular pulses of 10 ms (n = 10 in Neuro-2a Cells for all stimulation patterns). The stimulation of genetically modified Neuro-2a cells with stimulation pattern In transiently transfected Neuro-2a cells, POMC-EGFP fusion protein displayed a punctuated subcellular IV (25 Hz, 10 ms) led to a statistically significant higher amount of β-endorphin immunoreactivity (IR) released localization and transportation into cellular extensions (Fig. 1A) . EGFP used as control did not display such a in comparison to unstimulated cells (n = 10; p < 0.01) (Fig. 1C ). When stimulated in this way, the cells se-subcellular localization pattern and was primarily found in the cell body, but not in the cell extensions (Fig. 1B) .
creted 19.1% more β-endorphin than unstimulated control cells (222 ± 26 pg vs. 187 ± 21 pg/h). The enhanced POMC-EGFP partially colocalized with carboxypeptidase E (CPE), a marker for the regulated secretory path-release caused by stimulation pattern IV was not due to an increase in cell death, because the number of cells way, in transiently transfected Neuro-2a cells. The highest degree of colocalization was found in the tips of the (3.71 × 10 5 ± 1.95 × 10 4 for stimulated and 3.74 × 10 5 ± 3.45 × 10 4 for control cells, n = 3) and the percentage of cell processes (Fig. 1C) . Thus, overexpressed human POMC is partially targeted to the regulated secretory dead cells (3.06 ± 0.61% for stimulated and 3.02 ± 0.83% for control cells) were similar for both stimulated pathway in Neuro-2a cells. cells and controls. In contrast, stimulation patterns I (10 Enhanced Release of β-Endorphin Immunoreactivity Hz, 4 ms) and III (100 Hz, 4 ms) failed to increase the Upon Electrical Stimulation amount of β-endorphin released. While stimulation pattern II (25 Hz, 4 ms) had a detectable effect on the secre-Neuro-2a cells stably overexpressing human POMC were generated. For all further experiments a clonal tion of β-endorphin IR, the difference in the amounts released by stimulated and unstimulated cells was not significant. The common difference between stimulation pattern IV and patterns I-III was the prolonged duration of the delivered pulses.
DISCUSSION
A punctuated subcellular localization pattern within the cell body and cellular processes has been described for many molecules sorted into the regulated pathway in neuroendocrine cells. Among these molecules are carboxypeptidase E (CPE), cathepsin L, met-enkephalin, prohormone convertase 2, and POMC (1, 19, 21) . We confirmed that human POMC is sorted into the regulated secretory pathway by analyzing the subcellular localization of human POMC labeled with EGFP and the partial colocalization with endogenous CPE, a marker for the regulated secretory pathway in Neuro-2a cells. The fact that it is possible to stimulate the release of substances that are targeted to the regulated secretory pathway in specialized cells such as endocrine and neuroendocrine cells can be employed for therapeutical applications.
Chromaffin cells have been used for cell therapy in chronic pain (4,6). These cells release a mixture of different antinociceptive substances like catecholamines and enkephalins. It has been shown in animal models that chromaffin cell transplants in the spinal subarachnoid space reduce pain sensitivity for up to 3 months when stimulated with nicotine (12). Such nicotine stimulation increases the secretion of antinociceptive substances and leads to a reduction in pain responsiveness. Though the experiments demonstrate the feasibility of pharmacological stimulation, nicotine is inappropriate as a therapeutic agent. Nicotine is known to be toxic for the pancreas and is also the major psychoactive component of tobacco, causing dependence (9). Furthermore, nicotine can cause behavioral abnormalities in offspring as demonstrated on pregnant rats receiving intravenous most likely attributable to the dexamethasone treatment rather than the chemotherapeutic treatment (16) . Furthermore, the intake of an antibiotic like doxycyline raises the concern of selecting resistant bacteria (3). An hand, is feasible and has already been applied at the spinal cord (15) .
